Oruka Therapeutics, Inc.

ORKA · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$30,277-$24,574-$20,999-$25,781
Dep. & Amort.$20$19$16$16
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$5,077$0$0
Change in WC$1,965-$2,289-$3,034$3,980
Other Non-Cash$6,690-$1,378$3,148$2,967
Operating Cash Flow-$21,602-$23,145-$20,869-$18,818
Investing Activities
PP&E Inv.-$99-$34-$13-$18
Net Acquisitions$0$0$0$0
Inv. Purchases$0-$107,999-$44,290$0
Inv. Sales/Matur.$0$112,893$87,169$0
Other Inv. Act.-$122,350$0$0-$329,938
Investing Cash Flow-$122,449$4,860$42,866-$329,956
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$109$0$29,394
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$169,908$0$0-$29,920
Financing Cash Flow$169,908$109$0-$526
Forex Effect$0$0$0$0
Net Chg. in Cash$25,857-$18,176$21,997-$349,300
Supplemental Information
Beg. Cash$65,396$83,572$61,575$410,875
End Cash$91,253$65,396$83,572$61,575
Free Cash Flow-$21,701-$23,179-$20,882-$18,836
Oruka Therapeutics, Inc. (ORKA) Financial Statements & Key Stats | AlphaPilot